Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.

Abstract
POSITRON EMISSION tomography (PET) with [18F]fluorodeoxyglucose (FDG) has potential for demonstrating tumor metabolic activity before structural changes can be detected by computed tomographic (CT) imaging. Previous evaluations of FDG PET for diagnosis and staging of recurrent colorectal cancer have demonstrated higher sensitivity and specificity than CT.1-5 We now report a prospective evaluation of the accuracy of PET in 134 studies that were performed in patients with known or suspected recurrent colorectal cancer, together with assessment of the impact of PET findings on patient treatment and treatment cost.